Anti-CD154 [IDEC-131 (Toralizumab)] Fc Silent Antibody, Human IgG1 kappa (CAT#: BioBet-F507P) Datasheet

Fc Silent Antibody

The Fc-mediated effector functions of antibodies include antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), and have been shown to be crucial for the therapeutic efficacy of most clinically approved antibodies. However, engaging immune effectors through FcγR and complement interactions may be detrimental to certain mAb mechanisms of action and so Fc-null or -silenced antibodies may be desired.

Creative Biolabs uses site-directed mutagenesis technology to generate Fc-silenced antibody with reduced effector functions. The mutated Fc domains eliminate the binding of Fc receptors (FcγR, FcR), thereby leading to a significant reduction in ADCC and CDC in comparison to WT IgG.